SPRCHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 1 Aug 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores SciSparc Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (97): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (5): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own SciSparc Ltd. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on SPRC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 73% of US stocks
Cheaper than 26% of US stocks
Cheaper than 82% of US stocks
Cheaper than 62% of US stocks
Higher than 8% of US stocks
Higher than 6% of US stocks
Higher than 98% of US stocks
Higher than 7% of US stocks
Higher than 6% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SPRC appears on the weeks it earns a place.
SciSparc Ltd. (NASDAQ:SPRC) shares declined more than 20% on Friday.
Why it matters — The sharp drop in share price could indicate a significant market reaction to recent company developments or broader market conditions.
SciSparc announced that its subsidiary NeuroThera Labs achieved a technological milestone with its quantum sampling workflow platform for clinical trials data analytics, demonstrating a complete end-to-end hybrid quantum-classical workflow for clinical data analytics.
Why it matters — The milestone signals continued progress in NeuroThera's technology development, which could enhance data analytics capabilities for clinical trials within SciSparc's broader CNS-focused portfolio.
SciSparc announced that its subsidiary NeuroThera Labs has successfully completed internal validation of a proprietary quantum sampling workflow platform for clinical trial data analysis, developed on the platform of an S&P 500 company.
Why it matters — This development shows SciSparc's subsidiary advancing its technological capabilities in clinical data analytics, which could strengthen the company's position in the CNS treatment space.
SciSparc's board of directors has decided to target the agentic artificial intelligence market, and the company has formed a Scientific Advisory Board for Artificial Intelligence and Cybersecurity.
Why it matters — This signals a strategic expansion beyond SciSparc's previous focus, potentially opening a new line of business in the growing AI sector.
As at 1 Aug 2026, SciSparc Ltd. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (97 of 100).
No analyst covering SciSparc Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SPRC are extrapolating price history, which says nothing about the business.
SciSparc Ltd. returned -86.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for central nervous system disorders.
The most recent item we track (Benzinga, 31 July 2026): "What's Going On With SciSparc Shares On Friday?". SciSparc Ltd. (NASDAQ:SPRC) shares declined more than 20% on Friday.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for central nervous system disorders. Its primary drug development programs include SCI-110, targeting Tourette syndrome, Alzheimer’s disease and agitation, and obstructive sleep apnea, and SCI-110 for autism spectrum disorder and status epilepticus, conducted through its majority-owned subsidiary NeuroThera Labs Inc. The company also advances intellectual property in areas such as opioid-N-acylethanolamine combinations for pain management, neuroplastogen therapies, and the MUSE system, an endoscopic device for gastroesophageal reflux disease treatment. Additionally, SciSparc sells hemp seed oil-based nutraceutical products, including gummies, oil capsules, creams, and beauty treatments, via online marketplaces. It pursues innovative initiatives like quantum computing-enabled 3D protein modeling to enhance AI-driven drug discovery for neurological conditions. Founded in 2004 and headquartered in Tel Aviv, Israel, SciSparc operates in the pharmaceuticals and biotech sectors, emphasizing cannabinoid technologies and related IP assets.
CEO Mr. Oz Adler CPA · 3 employees · Israel · https://scisparc.com